Apolipoprotein A-I (ApoA-I) mimetic peptide P2a by restoring cholesterol esterification unmasks ApoA-I anti-inflammatory endogenous activity in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 716-722

  Bucci, Mariarosaria ^a   Cigliano, Luisa ^a   Vellecco, Valentina ^a   D'Andrea, Luca Domenico ^b   Ziaco, Barbara ^b   Rossi, Antonietta ^a   Sautebin, Lidia ^a   Carlucci, Alessandro ^a   Abrescia, Paolo ^a   Pedone, Carlo ^b   Ianaro, Angela ^a   Cirino, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A1; CHOLESTEROL ESTER; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOENZYME; NITRIC OXIDE SYNTHASE; PEPTIDE P2A; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN A-I; CHOLESTEROL ESTERS; CYCLOOXYGENASE 2; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; ESTERIFICATION; HAPTOGLOBINS; MALE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 84857321015     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.189308     Document Type: Article

References (36)

1. Braeckman L, De Bacquer D, Delanghe J, Claeys L, and De Backer G (1999) Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis 143:383-388. (Pubitemid 29166920)
2. Buga GM, Frank JS, Mottino GA, Hendizadeh M, Hakhamian A, Tillisch JH, Reddy ST, Navab M, Anantharamaiah GM, Ignarro LJ, et al. (2006) D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J Lipid Res 47:2148-2160. (Pubitemid 44936125)
3. Burstein M, Scholnick HR, and Morfin R (1970) Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 11:583-595.
4. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, and Getz GS (1996) HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res 37:2662-2674.
5. Cigliano L, Pugliese CR, Spagnuolo MS, Palumbo R, and Abrescia P (2009) Haptoglobin binds the antiatherogenic protein apolipoprotein E - impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytes. FEBS J 276:6158-6171.
6. Cigliano L, Spagnuolo MS, Cuomo G, Valentini G, Niglio A, and Abrescia P (2005) Apolipoprotein A-I-dependent cholesterol esterification in patients with rheumatoid arthritis. Life Sci 77:108-120. (Pubitemid 40546380)
7. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, and de Beer FC (1986) Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261:9644-9651. (Pubitemid 17214087)
8. De Bacquer D, De Backer G, Langlois M, Delanghe J, Kesteloot H, and Kornitzer M (2001) Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 157:161-166. (Pubitemid 32539366)
9. Degoma EM and Rader DJ (2011) Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 8:266-277.
10. Delanghe J, Cambier B, Langlois M, De Buyzere M, Neels H, De Bacquer D, and Van Cauwelaert P (1997) Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis 132:215-219. (Pubitemid 27311013)
11. Esteve E, Ricart W, and Fernández-Real JM (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 24:16-31.
12. Furbee JW Jr, Francone O, and Parks JS (2001) Alteration of plasma HDL cholesteryl ester composition with transgenic expression of a point mutation (E149A) of human LCAT. J Lipid Res 42:1626-1635. (Pubitemid 33020095)
13. Gomaraschi M, Calabresi L, Rossoni G, Iametti S, Franceschini G, Stonik JA, and Remaley AT (2008) Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J Pharmacol Exp Ther 324:776-783. (Pubitemid 351185837)
14. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, and Grunfeld C (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45:1169-1196. (Pubitemid 38802622)
15. Kontush A and Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58:342-374. (Pubitemid 44394906)
16. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS, and Abraham NG (2005) D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111:3126-3134. (Pubitemid 40847791)
17. Langlois MR and Delanghe JR (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42:1589-1600. (Pubitemid 26354735)
18. Lewis KE, Kirk EA, McDonald TO, Wang S, Wight TN, O'Brien KD, and Chait A (2004) Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 110:540-545. (Pubitemid 39031170)
19. Libby P (2007) Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev 65:S140-S146.
20. Matuszek MA, Aristoteli LP, Bannon PG, Hendel PN, Hughes CF, Jessup W, Dean RT, and Kritharides L (2003) Haptoglobin elutes from human atherosclerotic coronary arteries - a potential marker of arterial pathology. Atherosclerosis 168:389-396. (Pubitemid 36703339)
21. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, et al. (2005) Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res 97:524-532. (Pubitemid 41361742)
22. O'Brien KD, McDonald TO, Kunjathoor V, Eng K, Knopp EA, Lewis K, Lopez R, Kirk EA, Chait A, Wight TN, et al. (2005) Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 25:785-790. (Pubitemid 40463870)
23. Parks JS and Rudel LL (1985) Alteration of high density lipoprotein subfraction distribution with induction of serum amyloid A protein (SAA) in the nonhuman primate. J Lipid Res 26:82-91. (Pubitemid 15133297)
24. Peterson SJ, Husney D, Kruger AL, Olszanecki R, Ricci F, Rodella LF, Stacchiotti A, Rezzani R, McClung JA, Aronow WS, et al. (2007) Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther 322:514-520. (Pubitemid 47105774)
25. Porta A, Cassano E, Balestrieri M, Bianco M, Picone R, De Stefano C, and Abrescia P (1999) Haptoglobin transport into human ovarian follicles and its binding to apolipoprotein A-1. Zygote 7:67-77. (Pubitemid 129639335)
26. Posadas I, Bucci M, Roviezzo F, Rossi A, Parente L, Sautebin L, and Cirino G (2004) Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol 142:331-338. (Pubitemid 38746169)
27. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116:3090-3100.
28. Rader DJ, Alexander ET, Weibel GL, Billheimer J, and Rothblat GH (2009) The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 50:S189-S194.
29. Rader DJ and Daugherty A (2008) Translating molecular discoveries into new therapies for atherosclerosis. Nature 451:904-913. (Pubitemid 351301745)
30. Salvatore A, Cigliano L, Bucci EM, Corpillo D, Velasco S, Carlucci A, Pedone C, and Abrescia P (2007) Haptoglobin binding to apolipoprotein A-I prevents damage from hydroxyl radicals on its stimulatory activity of the enzyme lecithin-cholesterol acyl-transferase. Biochemistry 46:11158-11168. (Pubitemid 47502782)
31. Salvatore A, Cigliano L, Carlucci A, Bucci EM, and Abrescia P (2009) Haptoglobin binds apolipoprotein E and influences cholesterol esterification in the cerebrospinal fluid. J Neurochem 110:255-263.
32. Sherman CB, Peterson SJ, and Frishman WH (2010) Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 18:141-147.
33. Spagnuolo MS, Cigliano L, and Abrescia P (2003) The binding of haptoglobin to apolipoprotein AI: influence of hemoglobin and concanavalin A. Biol Chem 384:1593-1596. (Pubitemid 38054882)
34. Spagnuolo MS, Cigliano L, D'Andrea LD, Pedone C, and Abrescia P (2005) Assignment of the binding site for haptoglobin on apolipoprotein A-I. J Biol Chem 280:1193-1198.
35. Subbaiah PV, Liu M, and Witt TR (1997) Impaired cholesterol esterification in the plasma in patients with breast cancer. Lipids 32:157-162. (Pubitemid 27093187)
36. Thomsen LL, Ching LM, and Baguley BC (1990) Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res 50:6966-6970. (Pubitemid 20361099)